ReviewJournal of immunology research2018
Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria.
Review in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- The Added-on ofIranian journal of medical sciences · 2023Trial
- Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Association between circulating thyroperoxidase (TPO), anti-TPO IgE, anti-TPO IgG, and different clinical outcomes in chronic urticaria: A hypothesis-generating study.The World Allergy Organization journal · 2025Article
- Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation.PloS one · 2024Article
- Occurrence and risk factors of mental disorders in patients with chronic urticaria.The World Allergy Organization journal · 2023Article
- Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).The World Allergy Organization journal · 2022Article
- Predictors of Response to Oral Medications and Low-Histamine Diet in Patients with Chronic Urticaria.Journal of immunology research · 2022Article
- Biomarkers of disease activity in patients with chronic spontaneous urticaria.Postepy dermatologii i alergologii · 2021Article
- A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.Advances in experimental medicine and biology · 2021Article
- Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.The World Allergy Organization journal · 2020Article
- Clinical Characterization of Patients with Chronic Spontaneous Urticaria according to Anti-TPO IgE Levels.Journal of immunology research · 2019Article
- Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications.Journal of asthma and allergy · 2019Article
- Cardiac Dysautonomia, Decreased Baroreflex Sensitivity and Increased Myocardial Workload in Patients with Chronic Spontaneous Urticaria: A Preliminary Report.Indian journal of dermatologyArticle
- Resistant Chronic Spontaneous Urticaria - A Case Series Narrative Review of Treatment Options.Allergy & rhinology (Providence, R.I.)Review
- Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. It represents the most common subtype of chronic urticaria and is gaining importance in civil society because of its association with impaired quality of life. Moreover, CSU has a growing impact on national health systems representing a great burden due to its variable rate of response to the approved therapies. In this scenario, the identification of clinical and molecular biomarkers is of pivotal importance. Some groups are trying to detect molecules which would be able to help clinicians in reaching a proper diagnosis; additionally, the opportunity to describe disease severity which leads to cluster patients in different groups could fill the gap in the numerous unmet clinical needs. Several biomarkers are currently being studied with the purpose to predict the response to a defined therapy; unfortunately, none of them are ready to be translated from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.